Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 18
1966 32
1967 39
1968 47
1969 63
1970 52
1971 81
1972 58
1973 49
1974 44
1975 60
1976 59
1977 75
1978 78
1979 103
1980 94
1981 107
1982 134
1983 159
1984 189
1985 246
1986 202
1987 207
1988 208
1989 261
1990 289
1991 244
1992 306
1993 314
1994 316
1995 299
1996 307
1997 337
1998 303
1999 324
2000 354
2001 371
2002 402
2003 446
2004 444
2005 492
2006 588
2007 567
2008 563
2009 652
2010 701
2011 768
2012 787
2013 791
2014 813
2015 889
2016 899
2017 831
2018 854
2019 903
2020 1017
2021 1031
2022 1006
2023 954
2024 287

Text availability

Article attribute

Article type

Publication date

Search Results

21,304 results

Results by year

Filters applied: . Clear all
Page 1
Epithelial ovarian cancer: Review article.
Sambasivan S. Sambasivan S. Cancer Treat Res Commun. 2022;33:100629. doi: 10.1016/j.ctarc.2022.100629. Epub 2022 Sep 8. Cancer Treat Res Commun. 2022. PMID: 36127285 Free article. Review.
PARP Inhibitors in Ovarian Cancer: A Review.
O'Malley DM, Krivak TC, Kabil N, Munley J, Moore KN. O'Malley DM, et al. Target Oncol. 2023 Jul;18(4):471-503. doi: 10.1007/s11523-023-00970-w. Epub 2023 Jun 3. Target Oncol. 2023. PMID: 37268756 Free PMC article. Review.
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study.
Colombo N, Gadducci A, Landoni F, Lorusso D, Sabbatini R, Artioli G, Berardi R, Ceccherini R, Cecere SC, Cormio G, De Angelis C, Legge F, Lissoni A, Mammoliti S, Mangili G, Naglieri E, Petrella MC, Ricciardi GRR, Ronzino G, Salutari V, Sambataro D, Savarese A, Scandurra G, Tasca G, Tomao F, Valabrega G, Zavallone L, Pignata S. Colombo N, et al. Gynecol Oncol. 2023 Aug;175:182-189. doi: 10.1016/j.ygyno.2023.05.065. Epub 2023 Jun 22. Gynecol Oncol. 2023. PMID: 37355448
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.
González-Martín A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, Freyer G, Backes F, Heitz F, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Malinowska IA, Shtessel L, Compton N, Mirza MR, Monk BJ. González-Martín A, et al. Eur J Cancer. 2023 Aug;189:112908. doi: 10.1016/j.ejca.2023.04.024. Epub 2023 May 3. Eur J Cancer. 2023. PMID: 37263896 Free article. Clinical Trial.
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Mirza MR, González-Martín A, Graybill WS, O'Malley DM, Gaba L, Stephanie Yap OW, Guerra EM, Rose PG, Baurain JF, Ghamande SA, Denys H, Prendergast E, Pisano C, Follana P, Baumann K, Calvert PM, Korach J, Li Y, Malinowska IA, Gupta D, Monk BJ. Mirza MR, et al. Cancer. 2023 Jun 15;129(12):1846-1855. doi: 10.1002/cncr.34706. Epub 2023 Apr 14. Cancer. 2023. PMID: 37060236 Clinical Trial.
21,304 results
You have reached the last available page of results. Please see the User Guide for more information.